Table 3 Inflammatory biomarkers in relationship to clinical features (longitudinal studies)
From: Inflammatory biomarkers in patients with sciatica: a systematic review
Study | Age (yr) | Duration (weeks) | Source | Technique | Substance | Clin O | Ass |
|---|---|---|---|---|---|---|---|
Schistad [15] | 41.3 (10) | 20.3 (19.9) | serum | ELISA | Il-6 | VAS | B = 0,64a |
Sturmer [23] | 44.8 (12.4) | acuteb | serum | latex agl | hsCRP | VAS > 4 | aOR = 3,4c |
Andrade [24] | 49 | N | NP Biopsy | mRNA qPCR | TNFa | VAS | r = 0,65 |
AF Biopsy | mRNA qPCR | TNFa | VAS | r = 0,06 | |||
LF Biopsy | mRNA qPCR | TNFa | VAS | r = 0,29 | |||
Andrade [25] | 41 | 13–26 | NP Biopsy | mRNA qPCR | IL-6 | VAS | r = 0,23 |
NP Biopsy | mRNA qPCR | IL-1b | VAS | r = 0,05 | |||
NP Biopsy | mRNA qPCR | IL-6 | VAS | r = −0,11 | |||
NP Biopsy | mRNA qPCR | IL-1b | VAS | r = 0,03 | |||
Pedersen [26] | 39.3 (18–58) | 32.3 + − 4.5 | serum | ELISA | IL-6 | VAS | F(1.0, 118) = 9,7 |
serum | ELISA | IL-8 | VAS | F(1.0, 118,0) = 6,9 | |||
Wang [27] | 37 + −13.3)d | 48 (+ − 29) | serum | ELISA | IL-6 | ODI | r = 0,394 |
serum | ELISA | TNFa | ODI | r = 0,629 | |||
serum | ELISA | IL-10 | ODI | r = 0,415 | |||
serum | ELISA | IL-8 | ODI | r = −0,133 | |||
Moen [28] | 40 (9) | > 8 | serum | PEA | inflammation score | VAS | positive Linear discriminant analysis |
Zu [29] | 34.0 + −12.3e | 48 (+ − 29)c | serum | ELISA | TNFa | ODI + VAS > 3 | r = 0,2 |
serum | ELISA | TNFa | ODI + VAS < 3 | r = 0,37 | |||
serum | ELISA | IL-4 | ODI + VAS > 3 | r = 0,09 | |||
serum | ELISA | IL-4 | ODI + VAS < 3 | r = 0,08 | |||
Chen [30] | 51.3 + −24.4 | N | NP biopsy | Western blot | IL-21 | VAS | r = 0.834 |